WEBULL
WebtradeDownload

Could FDA Approval Change The Bull Case For Haemonetics (HAE)?

Simply Wall St · 2d ago
  • Haemonetics reported past FDA approval of its PerQseal Elite vascular closure system for large bore arterial procedures using 14 to 22F sheaths, featuring a fully bioabsorbable patch and near instant hemostasis confirmed in the ELITE arterial study.
  • The addition of PerQseal Elite after the Vivasure Medical acquisition broadens Haemonetics' large bore closure portfolio and deepens its exposure to structural heart and endovascular procedure volumes.
  • We will now explore how Haemonetics' investment narrative could shift as PerQseal Elite's sutureless, bioabsorbable design enters the U.S. market.

Scan beyond Haemonetics and pinpoint other procedure focused businesses that could benefit from similar momentum using our curated list of 34 healthcare AI stocks.

Haemonetics Investment Narrative Recap

To own Haemonetics, you need to believe the company can keep turning its plasma, TEG and vascular closure platforms into steadier recurring revenue and healthier margins despite tariff pressure, high debt and uneven recent profitability. The FDA approval for PerQseal Elite fits that story by adding another differentiated closure option, but it does not on its own reset the near term outlook.

In the near term, the key swing factor is whether growth in plasma systems, software and TEG disposables continues to support margin resilience while leverage of about US$1.2b stays manageable. The biggest risk still sits in competitive and cost pressure. Higher tariffs, self insured medical costs and pricing tension could matter more to earnings than a single product approval.

The PerQseal Elite clearance connects directly with earlier progress in vascular closure, where Haemonetics reported low double digit growth in Q1 FY27 and supportive data from a 1,623 patient VASCADE MVP XL study. That existing momentum in interventional technologies gives PerQseal Elite an established commercial and clinical context instead of a cold start.

This matters because the thesis around Haemonetics increasingly depends on multiple product engines working together. Plasma systems with Persona PLUS, growing TEG 6s use and now a broader large bore closure portfolio all feed the same goal: more disposable volume, a richer mix and better operating leverage. Execution across these franchises still needs to offset tariff, margin and leverage constraints.

Haemonetics' current analyst narrative points to revenues of US$1.6b and earnings of US$248.7m by 2029, based on assumed revenue growth of 6.1% per year and an increase in earnings of about US$152.4m from US$96.3m today.

Uncover why Haemonetics' fair value indicates a 5% potential upside to its current price that could narrow quickly.

NYSE:HAE 1-Year Stock Price Chart
NYSE:HAE 1-Year Stock Price Chart

Exploring Other Perspectives

One alternate angle focuses on Haemonetics' Interventional Technologies segment. The most cautious analysts worry that the prior 9% FY26 revenue decline and OEM and PFA headwinds could limit how much PerQseal Elite eventually contributes. Those forecasters were only looking for about US$1.6b of 2029 revenue and US$241.8m of earnings, so their expectations leave more room for upside if perceptions of this approval shift.

Explore another Haemonetics fair value estimate, including one that suggests it could be worth just $124.50.

Decide For Yourself

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

Looking For More Investment Ideas Beyond Haemonetics?

If the PerQseal Elite story has you thinking about broader themes in medical technology, the Simply Wall St Screener can help you find other stocks that match your preferred mix of quality, risk and income potential.